RFBL Flexi Pack IPO: GMP at 0, focus shifts

RFBL Flexi Pack and Goldline Pharmaceutical are the two SME IPOs that open for subscription on May 12, keeping the primary market active even as mainboard issuance stays quiet. Social media discussion is now centered on grey market signals, lot-size affordability, and whether the offers look fully priced. RFBL Flexi Pack’s grey market premium (GMP) is being tracked closely because it is currently at ₹0, while Goldline’s GMP is quoted higher in multiple posts.

Primary market mood: SME issues take the spotlight

The week’s IPO chatter is largely about SME names because only two public issues are opening, and the mainboard segment is described as quiet. Both RFBL Flexi Pack and Goldline Pharmaceutical open on May 12 and close on May 14, which is shaping investor attention into a short window. Posts highlight that SME IPO participation can look different from mainboard issues because the ticket size can be materially higher. That difference is a key part of the sentiment debate for RFBL because its lot size is 3,000 shares. Several discussions also frame SME IPOs as more sensitive to grey market cues, especially for investors seeking listing-day momentum. At the same time, some commentary warns against relying on GMP alone and suggests focusing on fundamentals and financials. The net effect is a split tone: interest in the calendar, but caution on pricing and liquidity. RFBL is seeing more fundamental comparison content, while Goldline is seeing more GMP-led chatter.

RFBL Flexi Pack IPO timeline and key dates

RFBL Flexi Pack’s IPO is scheduled to open for subscription on Tuesday, May 12, 2026, and close on Thursday, May 14, 2026. The allotment is expected to be finalized on May 15, 2026, according to widely shared timelines. The shares are proposed to be listed on the NSE SME platform. Several posts cite May 19, 2026 as the tentative listing date, while also noting that the listing date is sometimes described as not yet announced. The IPO is described as a book-built issue. Another detail doing the rounds is that anchor investor bidding opens on Monday, May 11, 2026. The tight schedule is adding to the focus on day-to-day subscription data once the issue opens. For many retail participants, the practical question is whether sentiment changes by the final day if subscription builds late.

Issue structure: fresh issue and headline size

RFBL Flexi Pack IPO is described as entirely a fresh issue of 70,65,000 equity shares. The issue size is shared as about ₹35.33 crore, with some posts also rounding it to around ₹35.53 crore. The face value is stated as ₹10 per share in widely circulated summaries. Because the issue is a fresh issue, the discussion is mostly about how proceeds will be used rather than any offer-for-sale component. The company is described as Gujarat-based and engaged in manufacturing and trading printed multilayer flexible packaging materials. That business description is repeated in multiple sources and is a core part of the IPO narrative. A separate line in social chatter cites a post-issue market cap estimate of ₹116.58 crore at the upper price band, but this is presented as a market discussion point rather than an official exchange figure. Some investors are pairing that market cap mention with valuation comparisons to listed peers. Others are focusing on the more basic point that the offer is not large, but it is not micro-sized either for SME standards.

Price band, lot size, and the real ticket size

The price band is set at ₹47 to ₹50 per share, with ₹50 cited as the upper price band. The lot size is consistently shared as 3,000 shares, which makes the application amount sizable at the upper end of the band. Some coverage also states that investors need to bid for two lots together, a detail that materially changes the minimum outlay. In parallel, other summaries list the minimum order quantity as 3,000, which is why retail affordability is a recurring debate. This lot-size question is a central reason RFBL’s social sentiment differs from Goldline’s, where posts highlight a minimum investment figure of ₹25,800 for retail based on its lot rules. For RFBL, the conversation is less about small-ticket access and more about whether the expected risk-adjusted return justifies the higher capital block. Traders looking for short-term moves are also mindful that SME stocks can have different liquidity characteristics after listing. The result is that RFBL is being assessed by some as a “moderate allocation” idea, while others are avoiding it due to application size alone.

Grey market premium: flat reading, louder debate

A repeated data point across posts is that RFBL Flexi Pack IPO’s GMP is currently ₹0. One widely circulated table snapshot pegs GMP at ₹0 as of 11-05-2026 20:28, with an estimated listing price near ₹50 based on that indicator. The same sources interpret a ₹0 GMP as muted sentiment and limited listing gains “at this stage,” rather than a negative signal. In Marathi and Hindi coverage, RFBL is contrasted with Goldline Pharmaceutical, where GMP is quoted at ₹16 and some reports suggest a potential listing gain percentage based on grey market trends. That contrast is shaping the narrative that the week has one “hotter” IPO and one “steady” IPO. However, multiple posts also caution that GMP reflects unofficial trading and can change quickly during the subscription window. Some market commentary explicitly says grey market indications should not override a fundamentals-based decision. The practical takeaway is that RFBL’s early grey market read is neutral, so subscription numbers and investor category participation may become the next sentiment driver.

What social media is claiming on valuation and performance

Alongside the muted GMP, one strand of social content argues RFBL looks cheaper versus certain listed competitors on valuation. The same content claims the company is coming at about 9.75 times PE at the upper price band, and mentions peers like Uma Converter and “Sub Flex” with higher PE figures. It also cites an ROE figure of 60.18% and describes RFBL as significantly more profitable than listed competitors, based on those comparisons. Another set of claims includes revenue growth from ₹46 crore to ₹135 crore and profit after tax rising from ₹67 lakh to ₹8.33 crore, framed as high growth over recent years. There is also discussion of a capacity jump of about 116% and existing plant utilization of around 52%, presented as operating leverage potential. These points are circulating as investor pitches, not as audited excerpts within the shared posts, so investors are treating them as inputs to verify. Importantly, a separate comment in the same broader discussion says the issue appears fully priced based on its current financial status. That divergence is why RFBL sentiment looks divided even before subscription opens.

Use of proceeds: CapEx, working capital, and debt talk

Use of proceeds is one of the more concrete parts of the RFBL IPO discussion. Several reports say the company plans to use ₹12.41 crore for new machinery and expansion, and ₹17.76 crore for working capital. That breakdown is being shared widely in explainers and is central to the “growth funding” narrative. Separately, one coverage line says the company will use a large part of proceeds to reduce debt, which adds a slightly different framing to the same fund-raise. The market takeaway from these posts is that the IPO is positioned as balance-sheet and capacity support rather than a secondary exit. Because flexible packaging is linked to FMCG, food, pharma, and e-commerce supply chains in popular commentary, some investors are mapping the use of proceeds to expected demand. Others are focusing on execution risk, especially when CapEx and working capital both compete for cash generation. The use-of-funds split also matters for those who prefer clearer timelines for capacity ramp-up. Investors tracking the issue are likely to look for consistency across disclosures and media summaries.

RFBL vs Goldline: why one has buzzier GMP

The two SME IPOs opening on the same dates are being compared side by side, mainly on GMP and minimum investment. Goldline Pharmaceutical is described as raising ₹11.61 crore via an IPO of 27 lakh shares with a price band of ₹41 to ₹43. It is also described as a pharma products marketing company, and multiple posts say it will list on BSE SME. RFBL Flexi Pack, by contrast, is raising about ₹35.33 crore at a price band of ₹47 to ₹50 and is slated to list on NSE SME. Social coverage says Goldline is trading at a ₹16 GMP, while RFBL is at ₹0, creating an immediate difference in short-term sentiment. At the same time, RFBL is receiving more discussion about valuation comparisons and capacity expansion, which is a different style of investor interest. Below is a quick snapshot of the most repeated details from social and media summaries.

What investors are watching during May 12-14

With GMP flat, RFBL’s subscription figures across categories are expected to become the key sentiment signal during the open period. Traders looking for listing-day outcomes will likely track whether GMP moves off zero as the book builds. Longer-horizon SME participants are discussing whether proceeds deployment into machinery and working capital improves scale and cash flows over time. Many posts emphasize the importance of being selective, with one view saying only well-informed, cash-surplus, or risk-seeking investors should park moderate funds for a medium-term horizon. Investors are also watching timeline clarity, especially because some summaries describe May 19 as tentative and others say the listing date is not yet announced. The registrar is shared as Kfin Technologies Ltd., a detail retail investors use to track application status. Another watchpoint is the pricing debate: one camp calls the issue fully priced, while another camp argues the valuation discount to peers is meaningful. Because SME counters can behave differently post-listing, liquidity and circuit limits are also part of the implicit risk conversation, even if not always explicitly spelled out in posts. Ultimately, the sentiment setup going into day one is neutral-to-cautious, with a high dependence on live subscription momentum.